02.12.2010 • News • Merck & Co. • Biotechnology • Mergers & Acquisitions (M&A)

Merck Set to Buy Biotech Firm SmartCells

U.S. pharmaceutical company Merck & Co. is set to buy SmartCells Inc, a privately held biotechnology firm in the early stages of developing a new diabetes drug, the Wall Street Journal reported.

The deal for SmartCells would exceed $500 million if various milestones for development, regulatory approval and sales were met and could be announced as early as Thursday, a person familiar with the matter told the Journal.

A SmartCells deal would expand Merck's treatment offerings for diabetes. It already has two top-selling drugs for Type 2 diabetics in its portfolio.

Merck could not be reached for comment.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Top-Feature